Applicant, as named in the Orange Book

X4 Pharms

Next listed expiry: Xolremdi on 11 Dec 2038. 1 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Xolremdi mavorixafor	mavorixafor	218709	11 Dec 2038	patent

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.